TScan Therapeutics (TCRX) Competitors $4.41 -0.41 (-8.51%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TCRX vs. FATE, NKTX, VYGR, ADAP, ABSI, ZYME, CALT, APLT, ARDX, and BCYCShould you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Fate Therapeutics (FATE), Nkarta (NKTX), Voyager Therapeutics (VYGR), Adaptimmune Therapeutics (ADAP), Absci (ABSI), Zymeworks (ZYME), Calliditas Therapeutics AB (publ) (CALT), Applied Therapeutics (APLT), Ardelyx (ARDX), and Bicycle Therapeutics (BCYC). These companies are all part of the "medical" sector. TScan Therapeutics vs. Fate Therapeutics Nkarta Voyager Therapeutics Adaptimmune Therapeutics Absci Zymeworks Calliditas Therapeutics AB (publ) Applied Therapeutics Ardelyx Bicycle Therapeutics TScan Therapeutics (NASDAQ:TCRX) and Fate Therapeutics (NASDAQ:FATE) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, community ranking, dividends, analyst recommendations, profitability, earnings, valuation and risk. Which has higher valuation and earnings, TCRX or FATE? TScan Therapeutics has higher earnings, but lower revenue than Fate Therapeutics. TScan Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTScan Therapeutics$12.20M19.15-$89.22M-$1.06-4.16Fate Therapeutics$63.53M3.62-$160.93M-$1.65-1.22 Is TCRX or FATE more profitable? TScan Therapeutics has a net margin of -1,188.88% compared to Fate Therapeutics' net margin of -1,325.43%. Fate Therapeutics' return on equity of -45.88% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TScan Therapeutics-1,188.88% -58.72% -36.02% Fate Therapeutics -1,325.43%-45.88%-33.95% Do institutionals & insiders hold more shares of TCRX or FATE? 82.8% of TScan Therapeutics shares are owned by institutional investors. Comparatively, 97.5% of Fate Therapeutics shares are owned by institutional investors. 2.8% of TScan Therapeutics shares are owned by company insiders. Comparatively, 5.0% of Fate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, TCRX or FATE? TScan Therapeutics has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Fate Therapeutics has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Does the media refer more to TCRX or FATE? In the previous week, TScan Therapeutics had 5 more articles in the media than Fate Therapeutics. MarketBeat recorded 23 mentions for TScan Therapeutics and 18 mentions for Fate Therapeutics. TScan Therapeutics' average media sentiment score of 0.62 beat Fate Therapeutics' score of 0.18 indicating that TScan Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 5 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fate Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community believe in TCRX or FATE? Fate Therapeutics received 449 more outperform votes than TScan Therapeutics when rated by MarketBeat users. However, 79.49% of users gave TScan Therapeutics an outperform vote while only 68.28% of users gave Fate Therapeutics an outperform vote. CompanyUnderperformOutperformTScan TherapeuticsOutperform Votes3179.49% Underperform Votes820.51% Fate TherapeuticsOutperform Votes48068.28% Underperform Votes22331.72% Do analysts prefer TCRX or FATE? TScan Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 172.11%. Fate Therapeutics has a consensus price target of $6.89, indicating a potential upside of 241.03%. Given Fate Therapeutics' higher possible upside, analysts plainly believe Fate Therapeutics is more favorable than TScan Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Fate Therapeutics 1 Sell rating(s) 6 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.27 SummaryTScan Therapeutics and Fate Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.Click here to discover our #1 crypto for the market right now – poised for massive growth Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRX vs. The Competition Export to ExcelMetricTScan TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$233.62M$2.91B$5.06B$8.66BDividend YieldN/A1.79%5.09%4.06%P/E Ratio-4.1643.08101.8517.37Price / Sales19.15217.681,196.8169.07Price / CashN/A178.0140.9136.36Price / Book1.024.096.335.87Net Income-$89.22M-$42.42M$119.64M$225.66M7 Day Performance-23.70%-10.63%-5.12%-1.34%1 Month Performance-19.96%-6.02%-3.21%1.00%1 Year Performance-7.16%26.36%32.52%25.27% TScan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRXTScan Therapeutics2.4915 of 5 stars$4.41-8.5%$12.00+172.1%-7.2%$233.62M$21.05M-4.16100Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageFATEFate Therapeutics4.1486 of 5 stars$2.38-7.0%N/A-15.1%$291.53M$63.53M-1.39550Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageNKTXNkarta2.3504 of 5 stars$3.05-10.0%N/A+7.2%$239.23MN/A-1.62140VYGRVoyager Therapeutics4.6687 of 5 stars$6.83-2.6%N/A-13.9%$382.28M$250.01M24.39100Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageADAPAdaptimmune Therapeutics2.1677 of 5 stars$0.79-3.6%N/A+17.3%$210.76M$60.28M-2.27449Analyst ForecastAnalyst RevisionNews CoverageABSIAbsci1.5346 of 5 stars$3.64-15.0%N/A+104.3%$486.02M$5.72M-3.91210Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeZYMEZymeworks2.1009 of 5 stars$17.40+0.4%N/A+97.8%$1.19B$76.01M-11.60290CALTCalliditas Therapeutics AB (publ)0.1943 of 5 stars$40.00flatN/AN/A$1.19B$1.60B-21.62180News CoverageAPLTApplied Therapeutics4.4519 of 5 stars$9.90-3.3%N/A+338.9%$1.19B$9.99M-6.1530Short Interest ↓News CoverageARDXArdelyx4.0429 of 5 stars$4.59-6.1%N/A+23.3%$1.16B$124.46M-15.30267Short Interest ↑Analyst RevisionGap UpBCYCBicycle Therapeutics2.8616 of 5 stars$23.42-3.7%N/A+55.8%$1.16B$26.98M-7.12240Insider SellingShort Interest ↑ Related Companies and Tools Related Companies Fate Therapeutics Competitors Nkarta Competitors Voyager Therapeutics Competitors Adaptimmune Therapeutics Competitors Absci Competitors Zymeworks Competitors Calliditas Therapeutics AB (publ) Competitors Applied Therapeutics Competitors Ardelyx Competitors Bicycle Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TCRX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TCRX Stock Alerts